Drug intelligence / Profile preview

Curarina

Development stage: Unknown
Lead developer: Harras Pharma Curarina
Administration: Oral

Overview

Curarina is a traditional herbal medicinal product developed and marketed by Harras Pharma. The active ingredient is the pressed juice of fresh flowering *Echinacea purpurea* (purple coneflower). It is primarily indicated for the supportive treatment of recurrent infections of the upper respiratory tract, such as the common cold, and the lower urinary tract. Curarina acts as an immunostimulant, enhancing the body's non-specific defense mechanisms to help fight off viral and bacterial pathogens. It is typically available in oral liquid formulations, including drops and juices, and is registered in Germany as a traditional herbal medicine.

Brand names: CurarinaCurarina Echinacea
Other names: Echinacea purpurea juicePurpursonnenhut-Kraut-Presssaft

Beyond the preview

Go deeper on Curarina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curarina.

Explore the full profile